DE69222847T2 - Verfahren zur herstellung einer festen dispersion - Google Patents

Verfahren zur herstellung einer festen dispersion

Info

Publication number
DE69222847T2
DE69222847T2 DE69222847T DE69222847T DE69222847T2 DE 69222847 T2 DE69222847 T2 DE 69222847T2 DE 69222847 T DE69222847 T DE 69222847T DE 69222847 T DE69222847 T DE 69222847T DE 69222847 T2 DE69222847 T2 DE 69222847T2
Authority
DE
Germany
Prior art keywords
solid dispersion
producing
chemicals
twin
dissolving
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69222847T
Other languages
English (en)
Other versions
DE69222847T3 (de
DE69222847D1 (de
Inventor
Kouichi Nakamichi
Shougo Izumi
Hiroyuki Yasuura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Shinyaku Co Ltd
Original Assignee
Nippon Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=14589572&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69222847(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nippon Shinyaku Co Ltd filed Critical Nippon Shinyaku Co Ltd
Publication of DE69222847D1 publication Critical patent/DE69222847D1/de
Application granted granted Critical
Publication of DE69222847T2 publication Critical patent/DE69222847T2/de
Publication of DE69222847T3 publication Critical patent/DE69222847T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
DE69222847T 1991-04-16 1992-04-14 Verfahren zur herstellung einer festen dispersion Expired - Lifetime DE69222847T3 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP11255491 1991-04-16
JP112554/91 1991-04-16
PCT/JP1992/000470 WO1992018106A1 (en) 1991-04-16 1992-04-14 Method of manufacturing solid dispersion

Publications (3)

Publication Number Publication Date
DE69222847D1 DE69222847D1 (de) 1997-11-27
DE69222847T2 true DE69222847T2 (de) 1998-05-20
DE69222847T3 DE69222847T3 (de) 2005-09-15

Family

ID=14589572

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69222847T Expired - Lifetime DE69222847T3 (de) 1991-04-16 1992-04-14 Verfahren zur herstellung einer festen dispersion

Country Status (12)

Country Link
US (1) US5456923A (de)
EP (1) EP0580860B2 (de)
JP (1) JP2527107B2 (de)
KR (1) KR0182801B1 (de)
AT (1) ATE159426T1 (de)
AU (1) AU1537292A (de)
CA (1) CA2108575C (de)
DE (1) DE69222847T3 (de)
DK (1) DK0580860T4 (de)
ES (1) ES2111065T5 (de)
GR (1) GR3025864T3 (de)
WO (1) WO1992018106A1 (de)

Families Citing this family (273)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
JP3722293B2 (ja) 1991-12-18 2005-11-30 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 新規な薬学的固体分散物
US5968551A (en) 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
DE69327877T2 (de) * 1992-10-14 2000-10-05 Nippon Shinyaku Co Ltd Verfahren zur verschiebung eines kristallzustandes
US5811547A (en) * 1992-10-14 1998-09-22 Nippon Shinyaju Co., Ltd. Method for inducing crystalline state transition in medicinal substance
ATE223704T1 (de) * 1992-10-16 2002-09-15 Nippon Shinyaku Co Ltd Verfahren zur herstellung von wachsmatrizes
US20080075781A1 (en) * 1992-11-25 2008-03-27 Purdue Pharma Lp Controlled release oxycodone compositions
US20070275062A1 (en) * 1993-06-18 2007-11-29 Benjamin Oshlack Controlled release oxycodone compositions
IL110014A (en) 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US7740881B1 (en) 1993-07-01 2010-06-22 Purdue Pharma Lp Method of treating humans with opioid formulations having extended controlled release
US5879705A (en) * 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
WO1995005809A1 (fr) * 1993-08-20 1995-03-02 Nippon Shinyaku Co., Ltd. Preparation restant dans l'estomac, forme moulee gonflee, et procede de preparation
GB2281697A (en) 1993-09-14 1995-03-15 Euro Celtique Sa Laxative compositions in capsules
US5688510A (en) * 1993-11-18 1997-11-18 Nippon Shinyaku Co. Ltd. Process for producing stable medicinal composition, and pharmaceutical preparation
DE19509807A1 (de) * 1995-03-21 1996-09-26 Basf Ag Verfahren zur Herstellung von Wirkstoffzubereitungen in Form einer festen Lösung des Wirkstoffs in einer Polymermatrix sowie mit diesem Verfahren hergestellte Wirkstoffzubereitungen
GB9422154D0 (en) 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
US20020006438A1 (en) * 1998-09-25 2002-01-17 Benjamin Oshlack Sustained release hydromorphone formulations exhibiting bimodal characteristics
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
ES2210321T3 (es) * 1994-12-19 2004-07-01 Daiichi Pharmaceutical Co., Ltd. Preparacion granular de liberacion prolongada y procedimiento de produccion.
FR2736550B1 (fr) * 1995-07-14 1998-07-24 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
ATE240734T1 (de) * 1995-07-26 2003-06-15 Kyowa Hakko Kogyo Kk Zubereitung von xanthinderivaten als feste dispersion
TW487582B (en) 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
BR9706897B1 (pt) * 1996-05-20 2010-09-21 forma de dosagem farmacêutica.
US6139872A (en) * 1996-08-14 2000-10-31 Henkel Corporation Method of producing a vitamin product
JPH10114682A (ja) * 1996-10-11 1998-05-06 Shimizu Kagaku Kk グルコマンナン配合持効性内服用薬剤
US5955475A (en) * 1997-06-30 1999-09-21 Endo Pharmaceuticals Inc. Process for manufacturing paroxetine solid dispersions
DE69837903T2 (de) 1997-08-11 2008-02-14 Pfizer Products Inc., Groton Feste pharmazeutische Dispersionen mit erhöhter Bioverfügbarkeit
EP1741424B1 (de) 1997-08-11 2018-10-03 Pfizer Products Inc. Feste pharmazeutische Dispersionen mit erhöhter Bioverfügbarkeit
HN1998000115A (es) * 1997-08-21 1999-06-02 Warner Lambert Co Formas de dosificación farmacéuticas sólidas
US6013280A (en) * 1997-10-07 2000-01-11 Fuisz Technologies Ltd. Immediate release dosage forms containing microspheres
WO1999034780A1 (de) * 1998-01-12 1999-07-15 Bühler AG Verfahren und vorrichtung zum verkapseln von wirkstoffen
IE980115A1 (en) * 1998-02-16 2000-02-09 Biovail Internat Ltd Solubilizing delivery systems and method of manufacture
AU759264B2 (en) * 1998-05-27 2003-04-10 Euro-Celtique S.A. Preparations for the application of anti-inflammatory, especially antiseptic agents and/or agents promoting the healing of wounds, to the upper respiratory tract and/or the ear
DE19842914A1 (de) * 1998-09-18 2000-03-23 Basf Ag Testsystem zur Charakterisierung der Verträglichkeit von biologisch aktiven Substanzen und Polyvinylpyrrolidon
DE19842753A1 (de) 1998-09-18 2000-03-23 Bayer Ag Agitationsunabhängige pharmazeutische Retardzubereitungen und Verfahren zu ihrer Herstellung
US6350786B1 (en) † 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
US6806294B2 (en) 1998-10-15 2004-10-19 Euro-Celtique S.A. Opioid analgesic
US6455526B1 (en) 1998-12-16 2002-09-24 Aventis Pharmaceuticals, Inc. Biodegradable polymer encapsulated pharmaceutical compositions and method for preparing the same
OA11728A (en) * 1998-12-16 2005-02-01 Aventis Pharma Inc Biodegradable polymer encapsulated serotonin receptor antagonist and method for preparing the same.
DE60039377D1 (de) 1999-02-09 2008-08-21 Pfizer Prod Inc Zusammensetzungen basischer Arzneistoffe mit verbesserter Bioverfügbarkeit
US6706283B1 (en) * 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
EP1027886B1 (de) 1999-02-10 2008-07-09 Pfizer Products Inc. Pharmazeutische feste Dispersionen
JP2000281561A (ja) * 1999-03-26 2000-10-10 Ajinomoto Co Inc 新規溶媒法固体分散体製剤
DE19918325A1 (de) 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
US7300667B1 (en) 1999-05-27 2007-11-27 Euro-Celtique, S.A. Preparations for the application of anti-inflammatory, especially antiseptic agents and/or agents promoting the healing of wounds, to the lower respiratory tract
US7297344B1 (en) 1999-05-27 2007-11-20 Euro-Celtique, S.A. Preparations for the promotion of wound healing in the upper respiratory tract and/or ear
ES2274372T3 (es) 1999-05-27 2007-05-16 Euro-Celtique S.A. Uso de antisepticos en la fabricacion de un preparado farmaceutico para la prevencion o el tratamiento de inflamaciones en el interior del cuerpo humano.
DE19945982A1 (de) 1999-09-24 2001-03-29 Knoll Ag Geschwindigkeitsbestimmte Partikel
DE19949897A1 (de) * 1999-10-15 2001-04-19 Rainer Rogasch Formkörper und Verfahren zu dessen Herstellung
EP2295043A1 (de) 1999-10-29 2011-03-16 Euro-Celtique S.A. Hydrocodon-Formulierungen mit gesteuerter Freisetzung
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
WO2001034119A2 (en) 1999-11-12 2001-05-17 Abbott Laboratories Inhibitors of crystallization in a solid dispersion
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
TR200201617T2 (tr) 1999-12-23 2002-10-21 Pfizer Products Inc. Kuvvetlendirilmiş ilaç konsantrasyonları sağlayan farmasötik kompozisyonlar
KR20030019326A (ko) * 2000-03-21 2003-03-06 니뽄 신야쿠 가부시키가이샤 방출 제어형 경구 투여 제제
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
DE10031044A1 (de) 2000-06-26 2002-01-03 Bayer Ag Endoparasitizide Mittel zur freiwilligen oralen Aufnahme durch Tiere
JP3563070B2 (ja) * 2000-07-17 2004-09-08 山之内製薬株式会社 経口吸収改善医薬組成物
US7115279B2 (en) 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
US20040013736A1 (en) * 2000-09-25 2004-01-22 Tomio Nakano Process for producing medicinal solid dispersion
CN101317825A (zh) 2000-10-30 2008-12-10 欧罗赛铁克股份有限公司 控释氢可酮制剂
ITMI20010141A1 (it) * 2001-01-26 2002-07-26 Giuliani Spa Procedimento per la preparazione di composizioni farmaceutiche o dietetiche per la veicolazione nell'intestino di sostanze labili
GB0104752D0 (en) * 2001-02-27 2001-04-18 Astrazeneca Ab Pharmaceutical compositions
CA2439366A1 (en) * 2001-02-27 2002-09-06 Julie Cahill Pharmaceutical formulation comprising bicalutamide
US6465014B1 (en) * 2001-03-21 2002-10-15 Isp Investments Inc. pH-dependent sustained release, drug-delivery composition
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
UA81224C2 (uk) 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
KR20040011549A (ko) * 2001-06-22 2004-02-05 화이자 프로덕츠 인크. 저용해도 및(또는) 산-민감성 약물 및 중화된 산성중합체를 포함하는 제약 조성물
EP1269994A3 (de) 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmazeutische Zusammensetzungen die ein Arzneimittel und die Konzentration verbesserende Polymere enthalten
ES2333645T3 (es) * 2001-06-22 2010-02-25 Bend Research, Inc. Composiciones farmaceuticas de dispersiones de medicamentos y polimeros neutros.
JP2004534811A (ja) * 2001-06-22 2004-11-18 ファイザー・プロダクツ・インク ポリマーと薬剤の集合体を含む医薬組成物
ES2284871T3 (es) * 2001-06-22 2007-11-16 Pfizer Products Inc. Composiciones farmaceuticas que contienen una dispersion solida de farmaco poco soluble y un polimero potenciador de la solubilidad.
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
SE0103424D0 (sv) * 2001-10-15 2001-10-15 Astrazeneca Ab Pharmaceutical formulation
US7491407B2 (en) * 2001-10-31 2009-02-17 North Carolina State University Fiber-based nano drug delivery systems (NDDS)
AR038375A1 (es) * 2002-02-01 2005-01-12 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
EP1920766B1 (de) 2002-02-01 2017-08-23 Bend Research, Inc Pharmazeutische Zusammensetzungen amorpher Dispersionen von Wirkstoffen und lipophiler mikrophasenbildender Materialien
KR20040083493A (ko) * 2002-02-01 2004-10-02 화이자 프로덕츠 인크. 콜레스테릴 에스테르 전달 단백질 억제제의 제어 방출형제약상 제형
KR100664822B1 (ko) 2002-02-01 2007-01-04 화이자 프로덕츠 인코포레이티드 변형된 분무-건조 장치를 이용한 균질한 분무-건조된 고체비결정성 약물 분산액의 제조 방법
US20030204180A1 (en) * 2002-04-30 2003-10-30 Kimberly-Clark Worldwide, Inc. Temperature responsive delivery systems
ES2333318T3 (es) 2002-08-12 2010-02-19 Bend Research, Inc. Composiciones farmaceuticas de medicamentos con estructura semiordenada y de polimero.
ATE407670T1 (de) 2002-12-20 2008-09-15 Pfizer Prod Inc Dosierungsform enthaltend einen cetp-hemmer und einen hmg-coa reduktase hemmer
WO2004069180A2 (en) * 2003-01-31 2004-08-19 Smithkline Beecham Corporation Solid dispersion compositions
EP1594468A2 (de) * 2003-02-03 2005-11-16 Novartis AG Verfahren zur herstellung eines pharmazeutischen produktes in form einer festen dispersion
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
JP2007511500A (ja) * 2003-11-14 2007-05-10 ファイザー・プロダクツ・インク 肥満治療のためのｍｔｐ阻害剤の固体非晶性分散体
WO2005056542A1 (en) * 2003-12-09 2005-06-23 Pfizer Inc. Compositions comprising an hiv protease inhibitor
JP2007520543A (ja) 2004-02-04 2007-07-26 ファイザー・プロダクツ・インク 置換キノリン化合物
US20050238721A1 (en) * 2004-04-07 2005-10-27 Acquarulo Lawrence A Jr One step compounding extrusion of drug filled polymers
EP1750669A1 (de) * 2004-05-04 2007-02-14 Boehringer Ingelheim International Gmbh Solide pharmazeutische form mit einem ltb4-antagonist
GEP20094723B (en) 2004-05-25 2009-07-10 Pfizer Prod Inc Tetraazabenzo [e] azulene derivatives and analogs thereof
JP2008501009A (ja) * 2004-05-28 2008-01-17 ファイザー・プロダクツ・インク 性能を高めた医薬組成物
MY191349A (en) * 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
ES2644450T3 (es) 2004-12-31 2017-11-29 Dr. Reddy's Laboratories Ltd. Nuevos derivados de bencilamina como inhibidores de CETP
US8617604B2 (en) 2005-02-03 2013-12-31 Bend Research, Inc. Pharmaceutical compositions with enhanced performance
EP1690528A1 (de) * 2005-02-11 2006-08-16 Abbott GmbH & Co. KG Herstellung von Dosierungsformen mit einer festen Dispersion eines mikrokristallinen Wirkstoffs
US20100047338A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
US20080213339A1 (en) * 2005-08-02 2008-09-04 Roger Imboden Pharmaceutical Composition Containing Indometacin and/or Acemetacin
EP2664337B1 (de) 2005-09-27 2019-08-14 TissueTech, Inc. Amnion-Zubereitungen und gereinigte Zusammensetzungen und Anwendungsverfahren
US8187639B2 (en) 2005-09-27 2012-05-29 Tissue Tech, Inc. Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
US8022054B2 (en) 2005-11-28 2011-09-20 Marinus Pharmaceuticals Liquid ganaxolone formulations and methods for the making and use thereof
EP1832281A1 (de) 2006-03-10 2007-09-12 Abbott GmbH & Co. KG Verfahren zur Herstellung einer Feststoffdispersion eines aktiven Wirkstoffes
EP2056818B1 (de) 2006-08-11 2011-05-25 The Johns Hopkins University Zusammensetzungen und verfahren für nervenschutz
HUE028086T2 (en) 2006-09-22 2016-11-28 Pharmacyclics Llc Bruton tyrosine kinase inhibitors
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
US7638541B2 (en) * 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
US7607596B1 (en) 2007-03-07 2009-10-27 Exxpharma, LLC Process for enhancing the solubility of poorly soluble drugs
US8703204B2 (en) 2007-05-03 2014-04-22 Bend Research, Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer
US8309129B2 (en) 2007-05-03 2012-11-13 Bend Research, Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
US9545384B2 (en) 2007-06-04 2017-01-17 Bend Research, Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glocol succinate
WO2008149192A2 (en) 2007-06-04 2008-12-11 Pfizer Products Inc. Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
MX2010000617A (es) 2007-07-17 2010-05-17 Plexxikon Inc Compuestos y metodos para modulacion de cinasa, e indicaciones de estos.
AU2008279447A1 (en) * 2007-07-19 2009-01-29 Metabolex, Inc. N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 receptor for the treatment of diabetes and metabolic disorders
CA2990445C (en) 2007-08-21 2020-05-05 Board Of Regents, The University Of Texas System Thermo-kinetic mixing for pharmaceutical applications
US8263641B2 (en) 2007-09-10 2012-09-11 Calcimedica, Inc. Compounds that modulate intracellular calcium
US20100240711A1 (en) * 2007-09-21 2010-09-23 Shionogi & Co., Ltd. Solid preparation comprising npyy5 receptor antagonist
EP2601935A1 (de) * 2007-09-25 2013-06-12 Solubest Ltd. Zusammensetzungen mit lipophilen Wirkstoffen und Herstellungsverfahren dafür
WO2009053635A1 (fr) * 2007-10-11 2009-04-30 L'oreal Composition cosmetique structuree
FR2922100B1 (fr) * 2007-10-11 2009-12-11 Oreal Procede de preparation de particules semi-solides a interet cosmetique
US9724362B2 (en) 2007-12-06 2017-08-08 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
US9233078B2 (en) 2007-12-06 2016-01-12 Bend Research, Inc. Nanoparticles comprising a non-ionizable polymer and an Amine-functionalized methacrylate copolymer
US20090163561A1 (en) * 2007-12-21 2009-06-25 Url Pharma, Inc. Amorphous metaxalone and amorphous dispersions thereof
JP5711655B2 (ja) * 2008-03-31 2015-05-07 シマベイ セラピューティクス， インコーポレーテッド オキシメチレンアリール化合物およびその使用
WO2010027875A2 (en) 2008-08-27 2010-03-11 Calcimedica Inc. Compounds that modulate intracellular calcium
US20110160222A1 (en) * 2008-11-26 2011-06-30 Metabolex, Inc. Modulators of glucose homeostasis for the treatment of diabetes and metabolic disorders
WO2010067233A1 (en) 2008-12-08 2010-06-17 Pfizer Inc. 1,2,4 triazolo [4, 3 -a] [1,5] benzodiazepin-5 (6h) -ones as agonists of the cholecystokinin-1 receptor (cck-ir)
CA2761389A1 (en) 2009-02-05 2010-08-12 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
WO2010114928A2 (en) 2009-04-03 2010-10-07 F.Hoffmann-La Roche Ag Compositions and uses thereof
EP2421901B1 (de) 2009-04-24 2015-10-28 Tissue Tech, Inc. Zusammensetzungen mit hc-ha-komplex und verfahren zu ihrer verwendung
RU2012101214A (ru) 2009-06-16 2013-07-27 Пфайзер Инк. Лекарственные формы апиксабана
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
CN102666553B (zh) 2009-10-01 2015-05-06 赛马拜制药公司 取代的四唑-1-基-苯氧基甲基-噻唑-2-基-哌啶基-嘧啶盐
US7718662B1 (en) 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
NZ629615A (en) 2009-11-06 2016-01-29 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
CN102821754B (zh) * 2010-03-26 2014-06-18 陶氏环球技术有限责任公司 多层熔融挤出膜
US20110236666A1 (en) * 2010-03-26 2011-09-29 Hall Mark J Melt-extruded film
KR20130080004A (ko) * 2010-03-26 2013-07-11 다우 글로벌 테크놀로지스 엘엘씨 용융-압출된 필름
EP2558866B1 (de) 2010-04-15 2016-08-17 Tracon Pharmaceuticals, Inc. Potenzierung einer antikrebs-wirkung durch eine kombinationstherapie mit ber-pfad-hemmern
WO2011139489A2 (en) 2010-04-27 2011-11-10 Calcimedica Inc. Compounds that modulate intracellular calcium
JP2013525448A (ja) 2010-04-27 2013-06-20 カルシメディカ，インク． 細胞内カルシウムを調節する化合物
US20130072519A1 (en) 2010-05-21 2013-03-21 Edward Lee Conn 2-phenyl benzoylamides
CA2800913C (en) 2010-06-03 2019-07-23 Pharmacyclics, Inc. The use of inhibitors of bruton's tyrosine kinase (btk)
EP2585048B1 (de) 2010-06-23 2018-04-11 CymaBay Therapeutics, Inc. Zusammensetzungen von 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidin
MX2013000201A (es) 2010-07-02 2013-08-21 Procter & Gamble Metodos para suministrar un activo de atencion sanitaria por medio de administrar articulos de cuidado personal que comprenden un filamento.
AU2011293201B2 (en) 2010-08-27 2015-11-05 Calcimedica Inc. Compounds that modulate intracellular calcium
JP5941069B2 (ja) 2011-02-07 2016-06-29 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． キナーゼ調節のための化合物および方法、ならびにそれに対する適応症
RU2013139701A (ru) 2011-02-17 2015-03-27 Ф. Хоффманн-Ля Рош Аг Способ контролируемой кристаллизации активного фармацевтического ингредиента из состояния переохлажденной жидкости экструзией горячего распада
AR085279A1 (es) 2011-02-21 2013-09-18 Plexxikon Inc Formas solidas de {3-[5-(4-cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico
DE102011015370A1 (de) * 2011-03-29 2012-10-04 Emodys Gmbh Matrix für eine orale Darreichungsform, Verfahren zu deren Herstellung sowie Verwendung derselben
WO2012149486A1 (en) 2011-04-28 2012-11-01 Tissuetech, Inc. Methods of modulating bone remodeling
ES2822301T3 (es) 2011-06-10 2021-04-30 Tissuetech Inc Métodos de procesamiento de tejidos de soporte fetal
US9199967B2 (en) 2011-08-18 2015-12-01 Dr. Reddy's Laboratories Ltd. Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (CETP) inhibitors
CN103917231B (zh) 2011-09-13 2016-09-28 药品循环有限责任公司 组蛋白脱乙酰酶抑制剂与苯达莫司汀的联合制剂及其用途
CN103958511A (zh) 2011-09-27 2014-07-30 雷迪博士实验室有限公司 作为胆固醇酯转移蛋白(CETP)抑制剂用于治疗动脉粥样硬化的5-苄基氨基甲基-6-氨基吡唑并[3,4-b]吡啶衍生物
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
MY168791A (en) 2012-01-06 2018-12-04 Abide Therapeutics Inc Carbamate compounds and of making and using same
IN2012DE00674A (de) 2012-03-07 2015-08-21 Nat Inst Of Pharmaceutical Education And Res Niper
SG11201405477XA (en) 2012-04-06 2014-11-27 Pfizer Diacylglycerol acyltransferase 2 inhibitors
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
CN110354132A (zh) 2012-06-04 2019-10-22 药品循环有限责任公司 布鲁顿酪氨酸激酶抑制剂的晶形
JP2015528001A (ja) 2012-07-11 2015-09-24 ティッシュテック，インク． Ｈｃ−ｈａ／ｐｔｘ３複合体を含む組成物およびその使用方法
DK2900674T3 (en) 2012-09-28 2017-07-03 Univ Washington Through Its Center For Commercialization RELATIONSHIPS AND PROCEDURES FOR PREVENTION, TREATMENT AND / OR PROTECTION AGAINST SENSITIVE CELL DEATH
WO2014059333A1 (en) 2012-10-12 2014-04-17 Calcimedica, Inc. Compounds that modulate intracellular calcium
KR102191562B1 (ko) * 2012-11-07 2020-12-15 에스케이바이오팜 주식회사 난용성 약물의 고체분산체 및 이의 제조방법
US20170071930A1 (en) 2012-11-19 2017-03-16 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions of cetp inhibitors
JP6150518B2 (ja) 2012-12-27 2017-06-21 花王株式会社 ポリフェノール組成物の製造方法
WO2014128564A2 (en) 2013-02-21 2014-08-28 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions of cetp inhibitors
AU2014236135A1 (en) 2013-03-14 2015-09-10 Thomas Jefferson University Androgen receptor down-regulating agents and uses thereof
EP2837391B1 (de) 2013-08-12 2017-05-10 Shin-Etsu Chemical Co., Ltd. Hypromellose-Acetat-Succinat zur Verwendung als Heißschmelzextrusionsträger, Heißschmelzextrusionszusammensetzung und Verfahren zur Herstellung eines Heißschmelzextrudats
US9808472B2 (en) 2013-08-12 2017-11-07 Tokai Pharmaceuticals, Inc. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
US9296882B2 (en) 2013-09-04 2016-03-29 Zzyzx Polymers LLC Methods for increasing throughput rates of solid-state extrusion devices
WO2015054283A1 (en) 2013-10-08 2015-04-16 Calcimedica, Inc. Compounds that modulate intracellular calcium
US20150104508A1 (en) * 2013-10-12 2015-04-16 Zzyzx Polymers LLC Devices, compositions, and methods for fabricating drug delivery systems
AU2014360446A1 (en) 2013-12-05 2016-06-09 Pharmacyclics, Llc Inhibitors of Bruton's tyrosine kinase
EP3104853B1 (de) 2014-02-10 2019-10-02 Respivant Sciences GmbH Behandlung mit mastzellenstabilisatoren für systemische erkrankungen
SI3104854T1 (sl) 2014-02-10 2020-09-30 Respivant Sciences Gmbh Stabilizatorji mastocitov za zdravljenje pljučnih bolezni
MX2016012008A (es) 2014-03-17 2016-12-07 Pfizer Inhibidores de diacilglicerol acil transferasa 2 para utilizarlos en el tratamiento de enfermedades metabolicas y relacionadas.
JP6537147B2 (ja) * 2014-03-18 2019-07-03 武田薬品工業株式会社 固体分散体
EP3134418A4 (de) 2014-04-23 2018-01-03 The Research Foundation for The State University of New York Schnelle und effiziente reaktion zur bioorthogonalen reaktion und borhaltige, zusammen damit nützliche heterocyclen
TW201603818A (zh) 2014-06-03 2016-02-01 組織科技股份有限公司 組成物及方法
WO2016031651A1 (ja) 2014-08-29 2016-03-03 花王株式会社 難溶解性ポリフェノール類を含有する固体分散体の製造方法
US9839644B2 (en) 2014-09-09 2017-12-12 ARKAY Therapeutics, LLC Formulations and methods for treatment of metabolic syndrome
US20160113906A1 (en) * 2014-09-19 2016-04-28 Board Of Regents, The University Of Texas System Methods of preparing extrudates
US9359316B1 (en) 2014-11-25 2016-06-07 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
EP3253766B1 (de) 2015-02-06 2019-09-04 University of Washington Verbindungen und verfahren zur vorbeugung oder behandlung von sensorischem haarzelltod
US10227333B2 (en) 2015-02-11 2019-03-12 Curtana Pharmaceuticals, Inc. Inhibition of OLIG2 activity
US20160243288A1 (en) 2015-02-23 2016-08-25 Tissuetech, Inc. Apparatuses and methods for treating ophthalmic diseases and disorders
CA2977521C (en) 2015-02-27 2024-03-19 Curtana Pharmaceuticals, Inc. 1-(aryl)-3-(heteroaryl) urea compounds and their use as olig2 inhibitors
AU2016226279B2 (en) 2015-03-03 2021-11-11 Pharmacyclics Llc Pharmaceutical formulations of Bruton's tyrosine kinase inhibtor
MA41827A (fr) 2015-03-27 2018-01-30 Pharmacyclics Llc Formes solvatées d'un inhibiteur de la tyrosine kinase de bruton
MA41828A (fr) 2015-03-27 2018-01-30 Pharmacyclics Llc Co-cristaux d'un inhibiteur de la tyrosine kinase de bruton
MX2017014344A (es) 2015-05-11 2018-04-11 Abide Therapeutics Inc Metodos para el tratamiento de la inflacion o el dolor neuropatico.
CN107847526A (zh) 2015-05-20 2018-03-27 组织技术公司 用于预防上皮细胞的增殖和上皮‑间充质转换的组合物和方法
MX2017015238A (es) 2015-05-28 2018-02-19 Dr Reddy´S Laboratories Ltd Composicion oral de celecoxib para tratamiento de dolor.
US10265296B2 (en) 2015-08-07 2019-04-23 Respivant Sciences Gmbh Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
EP3331522A1 (de) 2015-08-07 2018-06-13 Patara Pharma LLC Verfahren zur behandlung von mastzellbedingten erkrankungen mit mastzellstabilisatoren
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
EP3340982B1 (de) 2015-08-26 2021-12-15 Achillion Pharmaceuticals, Inc. Verbindungen zur behandlung von immun- und entzündungserkrankungen
US20170209462A1 (en) 2015-08-31 2017-07-27 Pharmacyclics Llc Btk inhibitor combinations for treating multiple myeloma
JP2019505498A (ja) 2015-12-16 2019-02-28 ザ・ウォルター・アンド・エリザ・ホール・インスティテュート・オブ・メディカル・リサーチ Ｎｋ細胞におけるサイトカイン誘導性ｓｈ２タンパク質の阻害
MA43649A (fr) 2016-01-19 2018-11-28 Janssen Pharmaceutica Nv Formulations/compositions comprenant un inhibiteur de btk
WO2017125424A1 (en) 2016-01-19 2017-07-27 Janssen Pharmaceutica Nv Formulations/compositions comprising a btk inhibitor
TW201733600A (zh) 2016-01-29 2017-10-01 帝聖工業公司 胎兒扶持組織物及使用方法
US10851123B2 (en) 2016-02-23 2020-12-01 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
CN116509869A (zh) 2016-04-04 2023-08-01 希诺皮亚生物科学公司 使用曲匹地尔治疗锥体外系综合征
CA3024556A1 (en) 2016-05-12 2017-11-16 The Regents Of The University Of Michigan Ash1l inhibitors and methods of treatment therewith
BR112018071722B1 (pt) 2016-05-13 2024-02-27 Merck Patent Gmbh Uso do amino açúcar como plastificante, composição em pó e seu processo de produção
WO2017194578A1 (en) 2016-05-13 2017-11-16 Merck Patent Gmbh Particle size and distribution of polymer for melt extrusion application
JP2019516773A (ja) 2016-05-25 2019-06-20 コンセントリック アナルジジックス，インク． 改善された局所麻酔のための局所麻酔薬及び血管収縮薬と組み合わせたフェノールｔｒｐｖ１アゴニストのプロドラッグ
WO2017205762A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205769A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205766A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
CA3029262A1 (en) 2016-06-27 2018-01-04 Achillion Pharmaceuticals, Inc. Quinazoline and indole compounds to treat medical disorders
EP3957629B1 (de) 2016-07-18 2023-09-06 Arthrosi Therapeutics, Inc. Verfahren zur herstellung von deuteriertem hydroxy-benzbromaron und deren zwischenprodukten
EP3493807A1 (de) 2016-08-03 2019-06-12 CymaBay Therapeutics, Inc. Oxymethylenarylverbindungen zur behandlung von entzündlichen gastrointestinalen krankheiten oder gastrointestinalen leiden
AR109179A1 (es) 2016-08-19 2018-11-07 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
JP7028860B2 (ja) 2016-08-26 2022-03-02 カーテナ ファーマシューティカルズ，インク． Ｏｌｉｇ２活性の阻害
EP3506893A4 (de) 2016-08-31 2020-01-22 Respivant Sciences GmbH Cromolynzusammensetzungen zur behandlung von chronischem husten aufgrund von idiopathischer pulmonaler fibrose
WO2018067341A1 (en) 2016-10-07 2018-04-12 Patara Pharma, LLC Cromolyn compositions for treatment of pulmonary fibrosis
EP3534883A1 (de) 2016-11-07 2019-09-11 Merck Patent GmbH Kapsel mit sofortiger freigabe auf der basis eines heissschmelzextrudierten polyvinylalkohols
EP3534882A1 (de) 2016-11-07 2019-09-11 Merck Patent GmbH Antialkoholinduzierte sturzentleerungstablette auf der basis von polyvinylalkohol
KR20190082848A (ko) 2016-11-07 2019-07-10 메르크 파텐트 게엠베하 폴리비닐 알코올을 기재로 하는 제어 방출 정제 및 이의 제조
WO2018093950A1 (en) 2016-11-16 2018-05-24 Abide Therapeutics, Inc. Pharmaceutical formulations
PE20191239A1 (es) 2016-11-16 2019-09-16 Abide Therapeutics Inc Formas cristalinas de un inhibidor de magl
CA3056030A1 (en) 2017-03-10 2018-09-13 Pfizer Inc. Novel imidazo[4,5-c]quinoline derivatives as lrrk2 inhibitors
CN109320428A (zh) * 2017-08-01 2019-02-12 浙江普利药业有限公司 一种马来酸曲美布汀晶型及其制备方法
EP3675865A4 (de) 2017-09-01 2021-06-02 University of Washington Kristalline formen von verbindungen zur vorbeugung oder behandlung von sensorischem haarzelltod
EP3706867A4 (de) 2017-11-07 2021-08-11 The Regents Of The University Of Michigan Therapeutische kombination zur behandlung von cerebellärer ataxie
US10632209B2 (en) 2017-11-10 2020-04-28 The Regents Of The University Of Michigan ASH1L inhibitors and methods of treatment therewith
WO2019113469A1 (en) 2017-12-07 2019-06-13 The Regents Of The University Of Michigan Nsd family inhibitors and methods of treatment therewith
US11685722B2 (en) 2018-02-28 2023-06-27 Curtana Pharmaceuticals, Inc. Inhibition of Olig2 activity
EP4155293A1 (de) 2018-06-07 2023-03-29 The Regents of The University of Michigan Prc1-inhibitoren und verfahren zur behandlung damit
EP3830078A4 (de) 2018-07-27 2022-03-30 Concentric Analgesics, Inc. Pegylierte prodrugs von phenolischen trpv1-agonisten
US20230022157A1 (en) 2018-08-20 2023-01-26 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement factor d medical disorders
US20200069742A1 (en) 2018-08-29 2020-03-05 Myos Rens Technology Inc. Methods for alleviating, inhibiting or reversing muscle disuse atrophy in mammals
KR102614808B1 (ko) 2018-08-31 2023-12-19 화이자 인코포레이티드 Nash/nafld 및 관련 질환의 치료를 위한 조합물
US20200108102A1 (en) 2018-10-03 2020-04-09 Myos Rens Technology Inc. Spray dried follistatin product
EP3866773A4 (de) 2018-10-16 2022-10-26 Georgia State University Research Foundation, Inc. Kohlenmonoxid-prodrugs zur behandlung von erkrankungen
WO2020096660A1 (en) 2018-11-06 2020-05-14 Myos Rens Technology, Inc. Methods and compositions for improving skeletal muscle protein fractional synthetic rate
SG11202106304RA (en) 2018-12-31 2021-07-29 Biomea Fusion Llc Irreversible inhibitors of menin-mll interaction
US11833186B2 (en) 2019-02-01 2023-12-05 Myos Corp. Methods and compositions for improving quality of life and increasing activity in aging and chronically ill mammals
US20220265630A1 (en) 2019-03-15 2022-08-25 Unicycive Therapeutics Inc. Nicorandil derivatives
EP3883548A4 (de) * 2019-04-08 2022-11-09 Cosci Med-tech Co. Ltd. Verfahren zur verbesserung der solubilisierung von pharmazeutischen substanzen und produkte davon
JP2022529930A (ja) 2019-04-19 2022-06-27 ファイザー・インク Ｐａｈを処置するための抗増殖薬
US20220387402A1 (en) 2019-05-20 2022-12-08 Pfizer Inc. Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases
CA3144848C (en) 2019-06-28 2023-11-21 Pfizer Inc. 5-(thiophen-2-yl)-1h-tetrazole derivatives as bckdk inhibitors useful for treating various diseases
TW202115086A (zh) 2019-06-28 2021-04-16 美商輝瑞大藥廠 Bckdk抑制劑
TWI771766B (zh) 2019-10-04 2022-07-21 美商輝瑞股份有限公司 二醯基甘油醯基轉移酶２ 抑制劑
JP2022058085A (ja) 2020-02-24 2022-04-11 ファイザー・インク ジアシルグリセロールアシルトランスフェラーゼ２阻害剤とアセチル－ＣｏＡカルボキシラーゼ阻害剤との組合せ
JP2021134211A (ja) 2020-02-24 2021-09-13 ファイザー・インク Ｎａｆｌｄ／ｎａｓｈおよび関連疾患の処置のための組合せ
CN115427403A (zh) 2020-04-21 2022-12-02 H.隆德贝克有限公司 单酰基甘油脂肪酶抑制剂的合成
BR112022024527A2 (pt) 2020-06-09 2022-12-27 Pfizer Compostos de espiro como antagonistas do receptor de melanocortina 4 e usos dos mesmos
JP2023533982A (ja) 2020-07-10 2023-08-07 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Ｇａｓ４１阻害剤及びその使用方法
WO2022133064A1 (en) 2020-12-16 2022-06-23 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin-mll interaction
WO2022150525A1 (en) 2021-01-06 2022-07-14 Awakn Life Sciences Mdma in the treatment of alcohol use disorder
EP4337316A1 (de) 2021-05-11 2024-03-20 Awakn Ls Europe Holdings Limited Therapeutische aminoindanverbindungen und zusammensetzungen
EP4346788A2 (de) 2021-06-03 2024-04-10 Arcadia Medicine, Inc. Enantiomere entactogenzusammensetzungen und verfahren zu deren verwendung
CA3228627A1 (en) 2021-08-11 2023-02-16 Thomas Butler Covalent inhibitors of menin-mll interaction for diabetes mellitus
WO2023022912A1 (en) 2021-08-20 2023-02-23 Biomea Fusion, Inc. Crystalline form of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(1-oxo -2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide, an irreversible menin-mll inhibitor for the treatment of cancer
WO2023027966A1 (en) 2021-08-24 2023-03-02 Biomea Fusion, Inc. Pyrazine compounds as irreversible inhibitors of flt3
WO2023039240A1 (en) 2021-09-13 2023-03-16 Biomea Fusion, Inc. IRREVERSIBLE INHIBITORS OF KRas
WO2023086341A1 (en) 2021-11-09 2023-05-19 Biomea Fusion, Inc. Inhibitors of kras
TW202337429A (zh) 2021-12-01 2023-10-01 美商輝瑞股份有限公司 支鏈酮酸脫氫酶激酶（ｂｃｋｄｋ）抑制劑及／或降解劑
WO2023105387A1 (en) 2021-12-06 2023-06-15 Pfizer Inc. Melanocortin 4 receptor antagonists and uses thereof
TW202340177A (zh) 2021-12-30 2023-10-16 美商拜歐米富士恩股份有限公司 作為 flt3抑制劑之吡嗪化合物
WO2023139163A1 (en) 2022-01-19 2023-07-27 Awakn Ls Europe Holdings Limited 1,3-benzodioxole esters and their therapeutic use
WO2023156565A1 (en) 2022-02-16 2023-08-24 Awakn Ls Europe Holdings Limited Bridged ring compounds and their therapeutic use as cns agents
WO2023235618A1 (en) 2022-06-03 2023-12-07 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin
US20240010649A1 (en) 2022-07-06 2024-01-11 Oppilan Pharma Limited Crystalline forms of an s1p receptor modulator

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5257315A (en) * 1975-11-04 1977-05-11 Sandoz Ag Tablet for medical preparation
DE2549740A1 (de) * 1975-11-17 1977-05-18 Sandoz Ag Neue galenische formen und verfahren zu deren herstellung
US4230687A (en) * 1978-05-30 1980-10-28 Griffith Laboratories U.S.A., Inc. Encapsulation of active agents as microdispersions in homogeneous natural polymeric matrices
JPS5785316A (en) * 1980-11-14 1982-05-28 Kanebo Ltd Preparation of easily absorbable nifedipine preparation
JPS58109411A (ja) * 1981-12-23 1983-06-29 Shionogi & Co Ltd ニフエジピン固型製剤組成物
JPS6240277A (ja) * 1985-08-15 1987-02-21 Ajinomoto Co Inc 顆粒状食品の製造法
US4778676A (en) * 1985-12-20 1988-10-18 Warner-Lambert Company Confectionery delivery system for actives
DE3612212A1 (de) * 1986-04-11 1987-10-15 Basf Ag Verfahren zur herstellung von festen pharmazeutischen formen
DE3612211A1 (de) * 1986-04-11 1987-10-15 Basf Ag Kontinuierliches verfahren zum tablettieren
US4760094A (en) * 1986-10-21 1988-07-26 American Home Products Corporation (Del.) Spray dried acetaminophen
US4842761A (en) * 1988-03-23 1989-06-27 International Flavors & Fragrances, Inc. Compositions and methods for controlled release of fragrance-bearing substances
DE3812567A1 (de) * 1988-04-15 1989-10-26 Basf Ag Verfahren zur herstellung pharmazeutischer mischungen
DE3827061C1 (de) * 1988-08-10 1990-02-15 Deutsche Gelatine-Fabriken Stoess & Co Gmbh, 6930 Eberbach, De
DE3830353A1 (de) * 1988-09-07 1990-03-15 Basf Ag Verfahren zur kontinuierlichen herstellung von festen pharmazeutischen formen
AU645003B2 (en) * 1988-11-08 1994-01-06 Takeda Chemical Industries Ltd. Sustained release preparations
JP2893191B2 (ja) * 1988-11-08 1999-05-17 武田薬品工業株式会社 放出制御性マトリックス剤
IL92343A0 (en) * 1988-12-20 1990-07-26 Gist Brocades Nv Granulate for multiparticulate controlled release oral compositions,their preparation and oral pharmaceutical compositions containing them
US5102668A (en) * 1990-10-05 1992-04-07 Kingaform Technology, Inc. Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH
FR2670398B1 (fr) * 1990-12-14 1995-02-17 Roquette Freres Composition pulverulente directement compressible et procede d'obtention.
JP3722293B2 (ja) * 1991-12-18 2005-11-30 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 新規な薬学的固体分散物
ATE223704T1 (de) * 1992-10-16 2002-09-15 Nippon Shinyaku Co Ltd Verfahren zur herstellung von wachsmatrizes
DE19509807A1 (de) * 1995-03-21 1996-09-26 Basf Ag Verfahren zur Herstellung von Wirkstoffzubereitungen in Form einer festen Lösung des Wirkstoffs in einer Polymermatrix sowie mit diesem Verfahren hergestellte Wirkstoffzubereitungen
WO1996009115A1 (fr) * 1994-09-21 1996-03-28 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Adsorbant pour interleukines, procede d'elimination de celles-ci par adsorption et dispositif d'adsorption
HN1998000115A (es) * 1997-08-21 1999-06-02 Warner Lambert Co Formas de dosificación farmacéuticas sólidas
US5954175A (en) * 1997-09-02 1999-09-21 Northrop Grumman Corporation Modularized parallel drivetrain
EP0966269A1 (de) * 1997-10-07 1999-12-29 Fuiz Technologies Ltd. Rasch-freisetzende arzneiverabreichungsform
US6029764A (en) * 1997-11-12 2000-02-29 Case Corporation Coordinated control of an active suspension system for a work vehicle
DE60039377D1 (de) * 1999-02-09 2008-08-21 Pfizer Prod Inc Zusammensetzungen basischer Arzneistoffe mit verbesserter Bioverfügbarkeit
ATE433318T1 (de) * 1999-02-10 2009-06-15 Pfizer Prod Inc Osmotisches system zur verabreichung von wirkstoffen, die feste amorphe dispersionen enthalten
EP1027886B1 (de) * 1999-02-10 2008-07-09 Pfizer Products Inc. Pharmazeutische feste Dispersionen

Also Published As

Publication number Publication date
DE69222847T3 (de) 2005-09-15
ES2111065T3 (es) 1998-03-01
DK0580860T3 (da) 1998-05-25
US5456923A (en) 1995-10-10
DE69222847D1 (de) 1997-11-27
JP2527107B2 (ja) 1996-08-21
CA2108575C (en) 2002-10-22
EP0580860B1 (de) 1997-10-22
CA2108575A1 (en) 1992-10-17
EP0580860A4 (en) 1994-06-15
WO1992018106A1 (en) 1992-10-29
KR0182801B1 (ko) 1999-05-01
GR3025864T3 (en) 1998-04-30
EP0580860B2 (de) 2004-12-15
DK0580860T4 (da) 2005-03-21
AU1537292A (en) 1992-11-17
EP0580860A1 (de) 1994-02-02
ATE159426T1 (de) 1997-11-15
ES2111065T5 (es) 2005-06-16

Similar Documents

Publication Publication Date Title
DE69222847D1 (de) Verfahren zur herstellung einer festen dispersion
DE59204317D1 (de) Thermoplastische Formmassen aus semikristallinem und amorphem Polyamid, deren Verwendung und Verfahren zu ihrer Herstellung.
DE3887857T2 (de) Orientierte, geschmolzene, geblasene Fasern, Verfahren zur Herstellung derselben und aus diesen Fasern hergestellte Vliese.
DE68912825T3 (de) Polypropylen-Zusammensetzung und Verfahren zur Herstellung von Folien aus dieser Zusammensetzung.
BR8902877A (pt) Processo para a producao de compostos estabilizantes uv para polimeros organicos
DE69009658D1 (de) Verfahren zur Herstellung von einem antibakteriellen, geformten Gegenstand aus Polyolefinharz.
DE69012039T2 (de) Poly-hexamethylen-adipamid-Garn mit hoher Festigkeit und niedrigem Schrumpf und Verfahren zur Herstellung desselben.
DE3751977T2 (de) Verstärkte kunststoff-laminate zur verwendung bei der herstellung gedruckter schaltkreise verfahren zur herstellung der laminate und erhaltene produkte
DE69101495D1 (de) Verfahren zur Herstellung einer ophthalmischen Linse aus Kunststoff und eine so hergestellte ophthalmische Linse.
DE69031405D1 (de) Fasern aus einer Mischung von Para-Aramid und Polyvinylpyrrolidon und Verfahren zur Herstellung derselben
DE3750263T2 (de) Vernetzte polypropylenfasern, verfahren zur herstellung und nichtgewobene textilien daraus.
DE3484091D1 (de) Verstrecktes produkt aus kristallinischem polymer mit hoher festigkeit und hohem modul und verfahren zur herstellung desselben.
DE3788188T2 (de) Formgegenstand aus Kunstharz mit ausgezeichneter antistatischer Eigenschaft und Verfahren zu seiner Herstellung.
DE69127046D1 (de) Ölabstossende Polymerzusammensetzungen und ihre Verwendung zur Herstellung von geformten Körpern, die mit hoher Lösungsmittelstabilität und geringer Verschmutzungsneigung ausgestattet sind
DE69007682D1 (de) Verfahren zur Herstellung von färbbaren poly(paraphenylen-terephtalamid) Fasern mit kationischen Farbstoffen.
DE69023797D1 (de) Verfahren zur Herstellung von orientierten geformten Artikeln aus Mischungen von para-Aramid mit thermisch verfestigbaren Polymeren.
ATE13156T1 (de) Verfahren zur herstellung von aus polymeren bestehenden gegenstaenden.
DE69213559T2 (de) Tetravinylpyrazine-Verbindung, Verfahren zur Herstellung derselben und elektrolumineszentes Element und damit hergesteller nichtlinearer optischer Stoff
DE60001724D1 (de) Ein Verfahren zur Herstellung einer Leiter und eine durch dieses Verfahren hergestellte Leiter
AT362926B (de) Verfahren zur herstellung von einachsig gereckten formguetern wie folien, baender, fasern od.dgl. aus polymerem kunststoff
ATE120809T1 (de) Verfahren zur herstellung von monofilen aus einer ternären formmasse auf basis thermoplastischer kunststoffe und hieraus extrudierte monofile.
DE3788504T2 (de) Wärmebeständige optische Faser aus Kunststoff und Verfahren zur Herstellung derselben.
DE69127931T2 (de) Herstellung von Polymeren aus Kohlenmonoxid mit olefinisch ungesättigten Verbindungen
ES2087480T3 (es) Procedimiento para producir ataduras fragilizables en el curso del tiempo, dispositivos para realizar el procedimiento, y ataduras obtenidas por medio del procedimiento.
KR20000069731A (ko) 장방형 소재 제조방법

Legal Events

Date Code Title Description
8363 Opposition against the patent
8328 Change in the person/name/address of the agent

Representative=s name: HANSMANN & VOGESER, 81369 MUENCHEN

8366 Restricted maintained after opposition proceedings
R071 Expiry of right

Ref document number: 580860

Country of ref document: EP